Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 26Prostatic Neoplasms 5Stomach Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tongue Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 29Prednisone 27Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × ixabepilone × Clear all
NCT00052572 2013-06-24

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡